Intralesional acyclovir versus cryotherapy in treatment of plantar warts: A randomized controlled trial - 18/12/25
, Basant Helal, BSc, Shahira Ramadan, MDAbstract |
Background |
Plantar warts are known for their recalcitrant nature. Intralesional acyclovir injection has been recently tried for treatment of warts.
Objective |
Comparing the efficacy and safety of intralesional acyclovir versus cryotherapy in treatment of plantar warts.
Methods |
Sixty-eight patients with plantar warts were randomized into: one group (34 patients with a total of 51 warts) received intralesional acyclovir, and the other group (34 patients with a total of 72 warts) underwent cryotherapy. Patients in both groups received a maximum of 5 sessions with 2-week intervals.
Results |
Complete cure of plantar warts was observed in 68.6% in the intralesional acyclovir group versus 61.1% in the cryotherapy group ( P = .393). A significantly higher number of sessions was needed to achieve complete cure in the intralesional acyclovir group (3.8 versus 3 sessions, P = .001). The procedure was significantly more painful in the intralesional acyclovir group with an average visual analog scale score of 6.5 versus 4.65, P = .005).
Limitations |
Blinding was not feasible in this study because of the distinctly 2 different techniques of treatment modalities used.
Conclusion |
Intralesional acyclovir is a promising therapeutic modality for plantar warts, demonstrating similar efficacy to cryotherapy, but the procedure is significantly more painful.
Le texte complet de cet article est disponible en PDF.Key words : acyclovir, cryotherapy, plantar wart
Abbreviation used : VAS
Plan
| Funding sources: None. |
|
| Patient consent: Written informed consents were obtained from all participants. There are no recognizable patient photographs or other identifiable material. |
|
| IRB approval status: The study is in accordance with the Helsinki Declaration of 1975 and with the ethical standards of faculty of medicine, Cairo University and approved by the Research Ethical Committee (REC) with code (MS-254-2023). |
|
| Data availability statement: The data that support the findings of this study are not openly available and are available from the corresponding author upon reasonable request. |
Vol 94 - N° 1
P. 113-119 - janvier 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
